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Abstract: Articular cartilage covers the surface of synovial joints and enables joint movement.
However, it is susceptible to progressive degeneration with age that can be accelerated by either
previous joint injury or meniscectomy. This degenerative disease is known as osteoarthritis (OA) and
it greatly affects the adult population. Cell-based tissue engineering provides a possible solution
for treating OA at its earliest stages, particularly focal cartilage lesions. A candidate cell type for
treating these focal defects are Mesenchymal Stem Cells (MSCs). However, present methods for
differentiating these cells towards the chondrogenic lineage lead to hypertrophic chondrocytes and
bone formation in vivo. Environmental stimuli that can stabilise the articular chondrocyte phenotype
without compromising tissue formation have been extensively investigated. One factor that has
generated intensive investigation in MSC chondrogenesis is low oxygen tension or physioxia (2–5%
oxygen). In vivo articular cartilage resides at oxygen tensions between 1–4%, and in vitro results
suggest that these conditions are beneficial for MSC expansion and chondrogenesis, particularly in
suppressing the cartilage hypertrophy. This review will summarise the current literature regarding
the effects of physioxia on MSC chondrogenesis with an emphasis on the pathways that control tissue
formation and cartilage hypertrophy.
Keywords: mesenchymal stem cells; chondrogenesis; hypoxia; cartilage; hypertrophy; hypoxia
inducible factors; early osteoarthritis
1. Introduction
Articular cartilage is a tissue lining the surface of synovial joints that provides friction-free
movement and facilitates load-bearing. Chondrocytes are the specialised cells within the tissue that
create and maintain cartilage matrix that is primarily composed of aggrecan (a large proteoglycan) and
collagen II. Chondrocyte orientation and matrix distribution within the tissue generates an anisotropic
structure from the cartilage surface to the deep zone and outwards from the chondrocyte. These
cartilage zones are described as the superficial, middle/transitional, deep and calcified zones; whilst
the pericellular, territorial and interterritorial regions surround the chondrocyte. The differences in
matrix distribution within these zones and regions contribute to cartilage biomechanics, enabling it to
withstand high dynamic and compressive loads during joint loading [1,2].
Int. J. Mol. Sci. 2019, 20, 484; doi:10.3390/ijms20030484 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 484 2 of 28
However, articular cartilage is susceptible to progressive degeneration leading to changes in its
structure and function. This degenerative disease is described as osteoarthritis (OA). Early observable
events in OA include collagen fibrillation of the superficial layer that leads to loss of proteoglycans
and other matrix molecules. Chondrocytes begin to proliferate and form clusters with increased
matrix synthesis in response, whilst inflammatory cytokines stimulate the expression of matrix
metalloproteinases (MMPs) and aggrecanases (ADAMTS) that facilitate cartilage degradation [3,4].
Eventually chondrocytes reduce their proliferative and anabolic response and the degeneration
continues, whilst pain and changes in joint function become apparent and are clinical indicators
for OA.
It has been noted that there is an increased risk of OA within the knee joint due to previous joint
injury (e.g., anterior cruciate ligament (ACL) injury), excessive repetitive loading, joint dysplasia and
meniscectomy. According to the German Cartilage Registry (Deutsche Gesellschaft für Orthopäedie
und Unfallchirurgie (DGOU)) between October 2013–June 2014, 60% of treated cartilage defects were
degenerative, whilst a recent multi-centre study showed that of 400 patients, approximately 40% had
chondral injuries resulting from degenerative conditions [5,6]. In classifying the forms of OA that
can be treated, recent studies have described the term “early OA” [7–9]. This latter condition may be
amenable to regenerative medicine or tissue engineering therapies. An example of cartilage tissue
engineering is autologous chondrocyte implantation (ACI) that is currently being used to treat focal
cartilage defects. However, a high failure and re-operation rate has been observed when treating focal
degenerative lesions compared with post-trauma defects. One potential reason for their poor outcome
is the surrounding inflammatory environment that impairs cell-based solutions. In particular, IL-1β
has been shown to be a negative predictor for ACI treatment post-surgery [5,10]. Thus, a primary goal
for clinicians and scientists is to develop regenerative options that can be used to treat both focal and
diffuse early OA in this challenging environment.
Autologous articular chondrocytes are an established cell-based tissue engineering strategy for
treatment of large “focal traumatic” or “focal early OA” chondral or osteochondral defects of the knee
joint [6,11,12]. Mesenchymal stem cells (MSCs) can be isolated from a variety of sources including
bone marrow, adipose (liposuction or intrapatellar fat pad) or synovium with minimal donor site
morbidity [13–16] and have been shown to have chondrogenic potential, initially in vitro with the
creation of pellets or micromasses and the addition of the stimulatory growth factor, transforming
growth factor-beta (TGF-β) [17,18]. Scaffolds/biomaterials have been developed in which MSCs
are seeded or encapsulated, and then chondrogenically differentiated to create clinically relevant
chondrogenic implants that may be used to fill patient defects. However, in both pellets and scaffolds,
markers of chondrocyte hypertrophy (collagen X, MMP13) have been detected and upon implantation
in vivo, ectopic bone formation can occur [19]. Strategies to prevent hypertrophy and produce a stable
articular chondrocyte phenotype with its defined extracellular matrix are the principle goals of in vitro
cartilage tissue engineering.
Scientists have attempted to attain stable cartilage formation with environmental stimuli relevant
to the in vivo situation, e.g., biomechanical stimulation, lower oxygen tension and/or addition of
appropriate growth factors. The rationale for using low oxygen tension for cartilage tissue engineering
is the oxygen level within articular cartilage that ranges from 2–5% oxygen (Figure 1) [20–24]. The use
of growth factors (e.g., TGF-β), low oxygen tension and other stimuli for MSC chondrogenesis can also
be used to cause the redifferentiation of articular chondrocytes in either pellets or hydrogels. Adding
TGF-β under physioxia upregulates chondrogenic gene (sex-determining region Y–box 9 (SOX9), collagen
II alpha I (COL2A1) and aggrecan (ACAN)) expression and subsequent glycosaminoglycan (GAG)
and collagen II accumulation, whilst downregulating the expression of catabolic genes (e.g., MMP9,
MMP13), ADAMTS-4, ADAMTS-5) compared with cells in hyperoxic (atmospheric) conditions [25–32].
Similarly, OA chondrocytes cultured in the same low oxygen conditions also demonstrated an increase
in GAG deposition and a reduction in the expression of MMPs, although they had higher collagen
X alpha I (COL10A1) and MMP13 expression and lower GAG deposition compared with healthy
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chondrocytes [30,31]. Additionally, low oxygen culture can also counter the inhibitory effects caused
by the presence of inflammatory cytokines [29]. Thus, lowered oxygen tension could potentially help
to induce a stable chondrogenic phenotype in MSC chondrogenesis, and many studies have been
conducted to understand its effects on this process. The present review will summarise the literature
and evaluate the effects of low oxygen tension or physioxia on MSC chondrogenesis, evaluating the
outcomes of the various studies and the pathways that have been identified to be part of the cellular
response to it. A Pubmed search was performed; the date of the last search was 31 October 2018. The
keywords used for the gathering of relevant publications used the terms, “mesenchymal stem cells”
and “hypoxia” or “chondrogenesis” or “chondrocytes”. Publications since 2001 were evaluated for the
purposes of this review.
Figure 1. Schematic diagram describing the zones within articular cartilage and the changes in oxygen
tension from the superficial zone to calcified zone.
2. Physioxia and Cartilage
In vivo physiological oxygen tension (physioxia) within human articular cartilage ranges from
2–5%, whilst bone marrow physioxia has been measured at 7% oxygen (Figure 1) [20,21,23,24]. The
atmospheric oxygen level (20% oxygen) at which most typical tissue culture incubators operate is
actually non-physiological and represents hyperoxia [20,33].
In all of the studies summarised for this review, incubator oxygen tension (20%; hyperoxia) is
utilised as the ‘control’ for experiments done at physioxia even though the latter is closer to conditions
found in vivo. An alternative method to mimic some of the effects of physioxia is through chemical
induction, specifically on the pathway controlling the stability of hypoxia-inducible factor-1 alpha (HIF-1α)
that has been found to be essential for chondrocyte survival and cartilage homeostasis (Figure 2) [34,35].
In chemically-induced physioxia, cobalt chloride is the most extensively studied compound. Under
hyperoxia, HIF-1α is hydroxylated by prolyl hydroxylases (PHDs) and factor inhibiting HIFs (FIH),
resulting in its proteosomal degradation (Figure 2a). The process is catalysed by molecular oxygen,
iron ions, ascorbic acid and 2-oxoglutarate [36–38]. Cobalt chloride competes with iron ions for the
active site of PHD and prevents HIF-1α hydroxylation, thereby stimulating a physioxic response in
hyperoxic oxygen conditions. Other hydroxylase inhibitors have also been used to create a physioxia
mimicking response, specifically dimethyloxalylglycine (a competitive inhibitor of PHDs and FIHs)
and desferrioxamine (sequesters iron ions). Although this review primarily focusses on experiments
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that use altered incubator oxygen levels, studies utilising chemically-induced physioxic responses are
discussed where appropriate [36,39,40].Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 28 
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under (b) hypoxia/physioxia (2% oxygen), thus leading to nuclear translocation of HIF-1α that forms a 
complex with HIF-1β and co-factor p300, that results in upregulation of physioxia-responsive genes. 
Arrows describe the flow and stages involved in HIF-1α behavior under (a) normoxia/hyperoxia and 
(b) hypoxia/physioxia (dotted arrow depicts HIF-1α nuclear translocation). 
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oxygen consumption, thereby having a greater ATP production via oxidative phosphorylation. In 
comparison, physioxic MSC cultures had greater lactate production and reduced oxygen 
consumption compared with hyperoxic MSC cultures, resulting in greater energy production via 
glycolysis [54,56,57]. The increased utilisation of oxidative phosphorylation under hyperoxia 
generated reactive oxygen species that can enhance cellular senescence [58]. Furthermore, telomeres 
that control cellular aging were found to be longer for physioxia-cultured MSCs [46]. These 
investigations demonstrate a clear advantage of physioxia for MSC expansion. 
Studies have also demonstrated that stem cell markers that are typically associated with either 
embryonic or induced pluripotent stem cells (e.g., octamer-binding transcription 4 (OCT-4), 
stage-specific embryonic antigen (SSEA-1) are expressed on MSCs expanded in physioxia [59,60]. 
Consistent with this, physioxia-expanded MSCs can undergo osteogenesis and adipogenesis at later 
population doublings compared with those expanded in hyperoxia. However, there are also studies 
showing that osteogenesis is inhibited under physioxia and with physioxia expanded MSCs 
differentiated under hyperoxia, indicating that differences in oxygen tension can affect 
differentiation towards different musculoskeletal lineages [48,54,59]. The present review focusses on 
how physioxia affects MSC chondrogenesis in terms of the amount of matrix formation that occurs 
and the types of matrix molecules that are expressed. The influence on the latter is of particular 
interest, as hyperoxic in-vitro MSC chondrogenesis results in the expression of hypertrophic 
markers (e.g., collagen X, MMP13, alkaline phosphatase) that upon implantation in a nude mouse 
model result in ectopic bone formation in vivo [19]. 
Schematic diagram describing the activation of hypox a-inducible factor-1 alpha (HIF-1α).
(a) Under normoxic/hyperoxic (20% oxygen) conditions, HIF-1α is hydroxylated by r l l
prot
physioxia (2 oxyge ), t s l i t l l i
l it I - -f t , t t lt i l ti f i i - i e s.
rr ri t fl a stages involve in HIF-1α behavior under (a) normoxia/ r i
( ) i physioxia (dotted arrow depicts HIF-1α nuclear translocation).
3. MSC Isolation and Expansion under Physioxia
Investigators examining MSC proliferation under physioxia have demonstrated that the initial
plating of human bone marrow produced greater colony-forming units–fibroblasts (CFU-Fs) upon
culture in a low oxygen environment [41–44]. Furthermore, MSCs were able to proliferate at a shorter
cell doubling time and have consequent increased cell numbers in physioxia [43–46]. This pattern
has also been replicated in the majority of studies for chondrogenic cells from different tissue sources
(adipose and synovium) and other species (porcine, ovine and murine) [43,45,47–53].
Long-term culture under lowered oxygen conditions caused MSCs to reach greater population
doublings with reduced cellular senescence [46,52,54,55]. The latter phenomena has been postulated to
be due to the underlying cellular ATP metabolism. Under hyperoxia, MSCs have an increased oxygen
consumption, thereby having a greater ATP production via oxidative phosphorylation. In comparison,
physioxic MSC cultures had greater lactate production and reduced oxygen consumption compared
with hyperoxic MSC cultures, resulting in greater energy production via glycolysis [54,56,57]. The
increased utilisation of oxidative phosphorylation under hyperoxia generated reactive oxygen species
that can enhance cellular senescence [58]. Furthermore, telomeres that control cellular aging were found
to be longer for physioxia-cultured MSCs [46]. These investigations demonstrate a clear advantage of
physioxia for MSC expansion.
Studies have also demonstrated that stem cell markers that are typically associated with either
embryonic or induced pluripotent stem cells (e.g., octamer-binding transcription 4 (OCT-4), stage-specific
embryonic antigen (SSEA-1) are expressed on MSCs expanded in physioxia [59,60]. Consistent with
this, physioxia-expanded MSCs can undergo osteogenesis and adipogenesis at later population
doublings compared with those expanded in hyperoxia. However, there are also studies showing
that osteogenesis is inhibited under physioxia and with physioxia expanded MSCs differentiated
under hyperoxia, indicating that differences in oxygen tension can affect differentiation towards
different musculoskeletal lineages [48,54,59]. The present review focusses on how physioxia affects
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MSC chondrogenesis in terms of the amount of matrix formation that occurs and the types of matrix
molecules that are expressed. The influence on the latter is of particular interest, as hyperoxic in-vitro
MSC chondrogenesis results in the expression of hypertrophic markers (e.g., collagen X, MMP13,
alkaline phosphatase) that upon implantation in a nude mouse model result in ectopic bone formation
in vivo [19].
4. Physioxia and MSC Chondrogenesis
4.1. Chondrogenic Matrix Formation
A summary of the outcomes for the effects of physioxia on MSC chondrogenic matrix formation
are described in Tables 1 and 2. Mouse stromal cells in a pellet culture model demonstrated that
physioxia (1% oxygen) upregulated SOX9 gene expression and increased GAG deposition in the
matrix [61]. Later studies were in agreement with the described investigation, whilst also observing an
increase in pellet wet weight and an upregulation in COL2A1 and ACAN expression [46,62]. However,
there are also studies that found a downregulation in matrix gene expression (SOX9, COL2A1, ACAN)
and no effect on matrix formation [44,51,53,54,63–69]. One study using adipose-derived murine MSCs
cultured under physioxia demonstrated a reduction in both GAG and collagen II matrix content
compared to hyperoxia, in spite of larger pellet diameter [66]. It was assumed in these cases that
oxygen gradients had formed under hyperoxia, whereby a physioxic region develops within the central
regions of pellets or scaffolds that correspond to greater GAG and collagen II matrix deposition [63,70].
Donor variability has been shown to influence chondrogenic potential, especially in response to
low oxygen culture. Anderson et al. [33] investigated the effect of physioxia on MSC preparations
with different levels of chondrogenic potential. Their intrinsic chondrogenic capacity was based
on the amount of GAG produced relative to that formed by articular chondrocytes formed under
normal atmospheric conditions. It was demonstrated that in preparation with low GAG, there was
enhanced chondrogenesis under physioxia, whilst high GAG producing MSC preparations did
not get a significant enhancement from lower oxygen. Thus, the differences described in studies
displaying no influence of physioxia on MSC chondrogenesis could be related to the donor variability
in chondrogenic potential.
With this as a caveat, the majority of studies of MSC chondrogenesis either in pellet or scaffold
cultures indicates an increase in chondrogenic genes (COL2A1 and ACAN) and matrix formation under
physioxia [33,41–43,47,49,50,52,55,62,71,72,76–79,82,86–88,90,92,93,95,97]. Furthermore, it has also
been shown that physioxia is a more potent promoter of chondrogenesis than dynamic (compressive)
loading with no synergistic effect upon combining the parameters [78,98].
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Table 1. Summary of the key findings from publications examining the effect of physioxia on mesenchymal stem cell (MSC) chondrogenesis. Findings are relative
to hyperoxia.
Publication Cell Source Pellets or Scaffolds Oxygen Tension Results—Physioxia Response Relative to Hyperoxia
Robins et al., 2005 [61] Mouse ST2 stromal
cells/C3H10T1/2 cells
Pellet 1% O2 Sex-determining region–box 9 (SOX9) expression is
upregulated and induces greater glycosaminoglycan (GAG)
deposition. Increased hypoxia-inducible factor-1 alpha
(HIF-1α) expression; no change in hypoxia-inducible factor-1
beta (HIF-1β) expression
Wang et al., 2005 [71] Human adipose MSCs Scaffolds (4 × 106 cells/mL,
alginate beads)
5% O2 Greater anaerobic respiration as measured by lactate
production both under expansion and chondrogenesis.
Increased GAG and collagen content
Betre et al., 2006 [65] Human adipose MSCs Scaffolds (2 × 106 cells/scaffold;
elastin-like polypeptide
scaffold)
5% O2 Upregulation in SOX9 and downregulation in collagen X
alpha 1 (COL10A1)—reduction in collagen II alpha I (COL2A1)
and aggrecan (ACAN). No difference in GAG or collagen
content between conditions
Malladi et al., 2006 [66] Murine inguinal fat pad MSCs Pellets 2% O2 Reduced GAG/DNA and collagen content but larger
diameter pellets
Khan et al., 2007 [72] Infrapatellar fat pad MSCs Pellet 5% O2 HIF1α, hypoxia inducible factor-2 alpha (HIF2α), SOX5, SOX6,
SOX9, ACAN, COL2A1 and COL10A1 increased expression.
HIF2α had greater expression than HIF1α. Increased pellet
wet weight, GAG content and collagen II staining
Malladi et al., 2007 [73] Murine adipose MSCs (HIF-1α
deleted mice)
Pellets 2% O2 HIF-1α expressed by adipose MSCs. HIF-1α deleted MSCs
significantly decreased SOX9, ACAN and COL2A1
expression. HIF-1α deleted micromasses had reduced GAG
and collagen II deposition
Felka et al., 2009 [74] Human bone marrow MSCs Pellet 2% O2; 2 ng/mL IL-1β No difference in gene transcript levels. Larger pellets with
more matrix production. Physioxia increase chondrogenic
gene (SOX9, COL2A1, ACAN), pellet size and matrix
deposition with reduced expression in matrix
metalloproteinase (MMP1 and MMP13) in IL-1β inhibited
chondrogenesis
Pilgaard et al., 2009 [63] Adipose derived MSCs Pellets 15%, 10%, 5%, 1% O2 SOX9, collagen I alpha I (COL1A1), COL2A1 and ACAN
upregulated at 15% oxygen and donwregulated under
physioxia. Reduction in COL10A1 expression. Increased
matrix staining and GAG synthesis at 15%
oxygen—reduced at lower oxygen tension. Increased matrix
synthesis in central regions of ambient cultures due to
oxygen gradients—central regions increase chondrogenesis
in 15% oxygen culture
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Table 1. Cont.
Publication Cell Source Pellets or Scaffolds Oxygen Tension Results—Physioxia Response Relative to Hyperoxia
Baumgartner et al., 2010 [75] Human bone marrow MSCs Scaffold (20 × 106 cells/ml
fibrin hydrogel)
3% O2 Greater and earlier expression of COL2A1. Increased alcian
blue matrix staining
Buckley et al., 2010 [76] Porcine infrapatellar fat pad
MSCs
Scaffold (15 × 106 cells/mL in
2% agarose)
2% O2 Greater GAG and collagen II content with increased
staining in core region. Superior mechanical properties
Khan et al., 2010 [77] Human bone marrow MSCs Pellet 5% O2 Upregulated SOX6, COL2A1, ACAN, HIF1α and HIF2α
expression. Enhancement in pellet wet weight and GAG
content
Merceron et al., 2010 [64] Human adipose MSCs Pellets 5% O2 COL2A1 expression enhanced and no difference in ACAN
expression. No difference in matrix deposition
Meyer et al., 2010 [78] Porcine bone marrow MSCs Scaffold (15 × 106 cells/mL in
2% agarose)
5% O2 Greater GAG and collagen II content with increased staining
in central regions. Increase in dynamic and equilibrium
modulus. No synergistic effect with dynamic loading
Li and Pei, 2011 [55] Human synovial fetal
fibroblasts
Pellets 5% O2 SOX9, ACAN and COL2A1 expression were upregulated.
Larger pellets with greater GAG and collagen II content
Stoyanov et al., 2011 [79] Human bone marrow MSCs Scaffolds (4 × 106 cells/mL in
1.2% (w/v) alginate beads)
2% O2 Increase in SOX9 and COL10A1 expression. Greater GAG
and collagen II content. In the presence of GDF-5, increased
ACAN and COL2A1 expression compared to TGF-β groups
with reduced hypertrophy
Gawlitta et al., 2012 [80] Human bone marrow MSCs Pellets 5% O2 Reduced collagen X staining
Meretoja et al., 2013 [67] Bovine bone marrow MSCs Scaffolds (Poly (ε-caprolactone;
4.5 × 106 cells/mL,
monoculture or co-culture (30%
articular chondrocytes: 70%
MSCs))
5% O2 COL2A1 upregulated—further enhanced in co-culture. No
difference in GAG and collagen content in MSCs
monocultures—increased alkaline phosphastase (ALP) and
calcification under these conditions. MSC-Chondrocyte
co-cultures reduced MSC hypertrophy—chondrocytes
prevent this process
Portron et al., 2013 [81] Rabbit and human adipose
MSCs
Pellets; Scaffolds (2 × 106
cells/mL (rabbit) or 5 × 105
cells/mL (human) in Si-HPMC)
5% O2 Upregulation in COL2A1 and ACAN in both cell and culture
types. Increased collagen II and GAG deposition. In vivo
implantation of physioxia preconditioned scaffolds had
higher O’Driscoll scores
Leijten et al., 2014 [82] Human bone marrow MSCs Pellets 2.5% O2 SOX9, COL2A1 and ACAN gene expression upregulated
and COL10A1 and MMP13 gene expression downregulated.
Increased GAG staining for physioxia chondrogenesis.
Physioxic preconditioned chondrogenesis reduced
bone-like formation upon in vivo implantation
Munir et al., 2014 [70] Human adipose MSCs Pellets, Scaffolds (8 × 106
cells/mL in collagen type I/II
scaffold–Chondroglide TM)
5% O2 SOX9, COL1A1 and COL2A1 expression upregulated with
downregulated COL10A1. Increase in COL2A1/COL1A1
and COL2A1/COL10A1 ratios. Increased matrix staining at
periphery and more core deposition in hyperoxic
pellets—same in scaffolds
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Table 1. Cont.
Publication Cell Source Pellets or Scaffolds Oxygen Tension Results—Physioxia Response Relative to Hyperoxia
Zhu et al., 2014 [83] Human bone marrow MSCs Scaffold (20 × 106 cells/mL;
Hyaluronic acid hydrogel)
1% O2 Reduced hypertophic marker (COL10A1, MMP13, ALP)
expression in low cross-linking hydrgoels. Increased GAG
content. High cross-linking density and hyaluronic acid
concentration increased expression of hypertrophy markers
Portron et al., 2015 [84] Human adipose MSCs Pellets 5% O2 SOX9, ACAN and COL2A1 upregulation and
downregulation of COL10A1 and MMP13. No difference in
matrix staining
Markway et al., 2016 [85] Human bone marrow MSCs Pellets 2% O2; 7 days ± TNF-α (1
ng/mL) at 2% or 20% O2
Reduction in TNF-α generated loss in GAG content.
Reduced MMP2, MMP9 and MMP13; ADAMTS4/5
expression. TNF-α inhibited MSC chondrogenesis
Galeano-Garces et al., 2017
[86]
Human adipose MSCs PCL scaffolds and pellets 2% O2 HIF1A, SOX9, COL10A1 and indian hedgehog (IHH) were
significantly upregulated and COL1A1 downregulated in
pellet cultures. SOX9 and ACAN expression had increased
PCL scaffolds, whilst COL10A1 expression was higher in
hyperoxic cultures
Legendre et al., 2017 [87] Human bone marrow MSCs Collagen I/III sponges; TGF-β
and BMP2 chondrogenic
induction
3% O2 Significant upregulation in COL2A1 and an increase in
COL2A1/COL1A1 and COL2A1/COL10A1 ratio
Gomez-Leduc et al., 2017 [69] Human umbilical cord MSCs Collagen I/III sponges; TGF-β
and BMP2 chondrogenic
induction
5% O2 Lower expression of chondrogenic genes (SOX9, COL2A1
and ACAN). Downregulation in COL10A1 and MMP13
expression, and reduced collagen X protein expression.
Change in oxygen tension from hyperoxia (Day 0–7)
followed by physioxia (Day 7–21) helped to stabilise
chondrogenic phenotype with reduction in hypertrophic
gene expression (COL10A1, MMP13)
Rodenas-Rochina et al., 2017
[88]
Porcine bone marrow MSCs Polycaprolactone (PCL)
composite scaffolds and
PCL-hyaluronic acid coated
scaffolds
5%O2 Significant increase in GAG deposition—no difference in
collagen content. Greater collagen II staining
Bae et al., 2018 [47] Human synovium MSCs Pellets 5% O2 Significant upregulation in SOX9, COL2A1 and ACAN.
Downregulation in COL10A1. Increased GAG deposition
and collagen II protein expression with reduced collagen X
expression
Desance et al., 2018 [68] Equine umbilical cord MSCs Collagen I/III sponges; TGF-β
and BMP2 chondrogenic
induction
3% O2 No difference in chondrogenic gene (SOX9, COL2A1 and
ACAN) or hypertrophy gene (COL10A1, runt-related
transcription factor-2 (RUNX2)) expression. Hypertrophic
genes were expressed significantly lower than chondrogenic
genes
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Table 2. Summary of key findings from publications examining the effect of physioxia preconditioning on MSC chondrogenesis. Findings are relative to hyperoxia.
Publication Cell Source Pellets or Scaffolds Oxygen Tension Physioxia Chondrogenic Response Relative to Hyperoxia
Martin-Rendon et al., 2007
[89]
Bone marrow MSCs Pellets 1.5% O2 Upregulated and stabilised HIF-1α expression. Increase in
SOX9 gene expression and pellet wet weight
Xu et al., 2007 [49] Murine adipose MSCs Pellets 2% O2 COL2A1 upregulated; no difference in SOX9 and ACAN
gene expression. Downregulation in MMPs (MMP2, MMP3,
MMP13) and osteogenic genes (RUNX2, ALP). Physioxia
preconditioning increased proteoglycan deposition—no
influence of reoxygenation
Krinner et al., 2009 [41] Ovine bone marrow MSCs Pellets 5% O2 Enhancement in GAG and collagen II content
Markway et al., 2010 [90] Human bone marrow MSCs Pellets 2% O2 ACAN, COL2A1 and COL10A1 upregulated. Increased
GAG content and larger pellets
Ronziere et al., 2010 [91] Human bone marrow MSCs
and adipose MSCs (only
preconditioned)
Pellets 2% O2 No difference in COL2A1 and ACAN expression. Reduction
in hypertophic markers (COL10A1 and MMP13) in
physioxia preconditioned MSCs
Muller et al., 2011 [62] Human bone marrow MSCs Pellets, Scaffolds (4 × 105 cells
in 10% (w/v) gelatin)
4% O2 Upregulation in SOX9, COL2A1, ACAN and COL10A1 in
pellets and scaffolds. Larger pellets and increased GAG
content
Weijers et al., 2011 [46] Human adipose MSCs Pellets 1% O2 SOX9 and COL2A1 upregulated. Increase in GAG content
Adesida et al., 2012 [42] Human bone marrow MSCs Pellets 3% O2 Upregulation in SOX9, COL2A1 and ACAN;
downregulation in COL10A1. Enhanced GAG content and
collagen II staining. Increase in transforming growth
factor–beta receptor one and two (TGFBR1 and TGFBR2)
and HIF-2α expression
Duval et al., 2012 [92] Human bone marrow MSCs Scaffolds (5 × 106 cells/mL in
alginate beads)
5% O2 Increase in SOX5, SOX6, SOX9, ACAN and COL2A1 gene
expression and decrease in COL10A1, RUNX2 and ALP.
Greater GAG and collagen II content upon in vivo
implantation. Application of HIF-1α dominant negative
plasmid prevents anabolic response
Sheehy et al., 2012 [45] Porcine bone marrow MSCs Pellets; Scaffold (15 × 106
cells/mL, 2% agaose)
5% O2 Increase in GAG and collagen in both pellets and scaffolds
(develops a pericellular matrix). Reduction in ALP;
suppression in hypertrophy
Lee et al., 2013 [93] Human bone marrow MSCs Pellets 2% O2 SOX9, COL2A1 and ACAN expression upregulated and
COL10A1 and RUNX2 downregulated. Matrix staining for
GAG, collagen II and collagen X support findings. Reduced
staining for apoptotic markers (Caspase -3 and -8). Akt and
downstream targets, FOXO1 and FOXO3, were
phosphorylated—Inhibition of pathway, increased
hypertrophy (COL10A1 and RUNX2) and reduced response.
No effect on hyperoxic chondrogenesis
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Table 2. Cont.
Publication Cell Source Pellets or Scaffolds Oxygen Tension Physioxia Chondrogenic Response Relative to Hyperoxia
O’HEireamhoin et al., 2013
[49]
Human infrapatellar fat pad
MSCs
Pellets, scaffolds (20 × 106
cells/mL in 2% agarose or
fibrin)
5% O2 Increase in GAG and collagen II content in pellets. Only GAG
deposition increased within scaffolds—reduced collagen X
staining
Pattappa et al., 2013 [54] Human bone marrow MSCs Pellets 5% or 2% O2 No difference in GAG content
Ranera et al., 2013 [94] Equine bone marrow MSCs Pellets 5% O2 SOX9, COL2A1, ACAN, cartilage oligomeric matrix protein
(COMP) gene expression upregulated. Physioxia
preconditioned cells enhanced GAG content. HIF-1α
expression increased with time
Boyette et al., 2014 [44] Ovine bone marrow MSCs Pellets 5% O2 Enhanced chondrogenesis in physioxia differentiated cells but
inhibited differentiation for physioxia preconditioned cells
Kalpakci et al., 2014 [50] Dermis isolated MSCs Pellets 5% O2 Increased GAG and collagen content in physioxia
preconditioned MSCs; collagen II content was greater under
hyperoxia
Bornes et al., 2015 [43] Ovine bone marrow MSCs Scaffolds (1 × 107 cells/cm2 on
either collagen type I and
esterified hyaluronic acid
scaffolds)
3% O2 Upregulated ACAN and COL2A1 gene expression and
downregulation in COL10A1. Enhanced GAG and collagen II
content in both scaffold types
Anderson et al., 2016 [33] Human bone marrow MSCs Pellets 2% O2 COL2A1 and ACAN upregulated whilst COL10A1 and
MMP13 downregulated depending upon chondrogenic
capacity. Enhanced GAG production. MSCs with high
chondrogenic capacity stained for collagen X inspite of
physioxic culture
Henrionnet et al., 2016 [95] Human bone marrow MSCs Alginate beads 5% O2 Upregulated SOX9, COL2A1, ACAN and COMP,
downregulated RUNX2 and ALP expression. No change in
COL10A1 expression. Sequential hyperoxia then physioxia
increased COL2A1 and ACAN expression with reduction in
COL10A1 expression. No calcification
Hudson et al., 2016 [96] Human MSCs Collagen-alginate scaffold 5% O2 Greater GAG content and mechanical properties
Ohara et al., 2016 [53] Human synovial derived MSCs Pellets 5% O2 No difference in pellet wet weight or matrix staining
Yasui et al., 2016 [52] Synovium MSCs Scaffolds (Sheet–like construct,
4 × 105 cells/cm2)
5% O2 Increase in SOX9, ACAN and COL2A1 expression. Increased
GAG and collagen II content
Bornes et al., 2018 [51] Ovine bone marrow MSCs HYAFF scaffolds 3% O2 No difference in COL2A1 and ACAN gene expression but
significant increase in GAG content after 14 days culture.
Significant downregulation in COL10A1 with concomitant
increase in COL2A1/COL10A1 ratio at day 4 and 14. No
difference in cartilaginous tissue formation in preconditioned
chondrogenic MSCs upon in vivo implantation
Lee et al., 2018 [97] Human bone marrow MSCs Pellets 1% O2 Upregulation in SOX9, COL2A1 and ACAN expression.
Increase in GAG deposition
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4.2. MSC Hypertrophy
The effect of physioxia on chondrogenic hypertrophy has been a focus of many studies.
A downregulation in hypertrophic (COL10A1) gene expression has been measured in the
majority of studies [33,42,43,47,51,63,65,69,70,80,82–84,87,92,93,95], although there is some recorded
upregulation [62,67,72] in this hypertophic marker. It has also been shown that the timing of
physioxic culture influences this process. Culture under physioxia after an initial 2 weeks of hyperoxic
culture significantly reduced the expression of hypertrophic genes and increased that of hypertrophy
antagonists, Gremlin-1 (GREM1), Frizzled-related protein (FRZB) and Dickkopf WNT (DKK1). These
antagonists were reduced and hypertrophic genes were upregulated upon hyperoxic culture [82].
As previously discussed, Anderson et al. [33] demonstrated the importance of low GAG and high
GAG MSC preparations on chondrogenic matrix production. Subsequent analysis of hypertrophy
genes indicated that despite a downregulation of COL10A1 in both MSC preparations, only high GAG
MSC donors expressed a significant difference relative to hyperoxic conditions. However, collagen
X staining was observed in physioxia-treated pellets independent of whether they were high or low
GAG MSCs. This also demonstrates differences in gene expression and protein data with respect
to hypertrophy, and this has been shown in a few studies [33,42,82,99]. Thus, physioxia suppresses
collagen X expression but does not completely inhibit its production.
A few studies have shown that physioxia also downregulates collagenases (MMP13) and
aggrecanases (ADAMTS-4 and ADAMTS-5) involved in cartilage hypertrophy. Examination of osteogenic
gene expression (runt-related transcription factor-2 (RUNX2), osteopontin and osteonectin) and calcium
deposition within the cartilaginous matrix was also found to be inhibited under physioxia [45,83,91].
In this instance, inhibited osteogenesis may be related to an underlying metabolism that favours a
glycolytic metabolism, which is a critical component for sustaining an articular chondrocyte phenotype
and thus, may also operate during MSC chondrogenic differentiation [57,59,71]. A microarray analysis
showed an upregulation in glycolysis pathway-associated enzymes under physioxia, indicating its
importance in developing a stable chondrocyte phenotype [82].
4.3. MSC Preconditioning and In Vivo Implantation
MSC that have been pre-expanded or preconditioned under physioxia prior to subsequent
chondrogenesis under the same conditions demonstrated an enhancement in matrix deposition and a
reduction in collagen X and other hypertrophy markers compared with non-preconditioned chondrogenic
MSCs differentiated under physioxia (summarised in Table 2) [41–43,45,46,48,49,52,62,89–91,93–95,97].
Martin-Rendon et al. (2007) showed that preconditioned MSCs had higher SOX9 gene expression and
subsequent pellet wet weight [89]. Physioxic preconditioned MSCs have demonstrated an increase
in gene expression and cartilage matrix formation, even when differentiated under hyperoxia, when
compared with non-preconditioned MSCs [42,43]. Examination of physioxia isolated MSCs has
been shown to have a significantly reduced expression in CD90 or Thy-1 expression under these
conditions [42]. Articular chondrocytes have been shown to not express CD90 in vivo but it is
expressed during in vitro culture, concomitant with a loss of chondrogenic potential [100]. Potentially,
a pre-selection process occurs under physioxia, whereby a chondroprogenitor population is isolated.
It might be possible to use CD90 or other cell surface markers to evaluate whether physioxia can select
for MSCs that have a high chondrogenic potential.
Subsequent implantation of physioxia-conditioned chondrogenic MSCs in vivo has been
shown to increase cartilage matrix formation (collagen II and GAG) compared with implanted
hyperoxic-conditioned MSCs. Furthermore, physioxia-preconditioned MSCs demonstrated reduced
bone-like formation in both nude mouse and rabbit models, unlike previous investigations using
hyperoxic MSCs in nude mouse models [81,82,92]. However, in larger animal models, despite
an increase in in vitro chondrogenic gene expression and matrix formation, subsequent in vivo
implantation provided no significant advantage relative to hyperoxic MSCs [51]. The sustained
low oxygen environment in vivo could eliminate the difference between physioxic and hyperoxic
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preconditioning that is seen in short-term in vitro cultures. Further studies are required to
understand whether physioxic preconditioned MSCs or chondrogenic implants are beneficial for
in vivo chondrogenesis, specifically in larger animal models.
4.4. Physioxia Prevents Cytokine Inhibited Chondrogenesis
To mimic the OA environment and evaluate the performance of MSC chondrogenic implants
for the treatment of focal defects, inflammatory cytokines have been used. IL-1β and TNF-α
have previously been demonstrated to inhibit MSC chondrogenesis under hyperoxia [74,85]. An
investigation showed that the reduction in matrix formation in the presence of IL-1β was suppressed
by physioxic culture [74]. In particular, the matrix degradative enzymes (MMP1, MMP3 and MMP13)
induced by IL-1β presence were reduced under physioxia. A recently published study reported similar
results, but it was noted that physioxia does not completely restore chondrogenesis to control levels in
the presence of IL-1β, and only low GAG MSC donors or physioxia responders displayed a significant
increase in chondrogenic gene expression and cartilage matrix formation [99].
A potential reason for the restoration of the chondrogenic phenotype in the presence of IL-1βmay
be related to the upregulation in TGF-β receptors I and II under physioxia chondrogenesis. In this
instance, chondrocytes in the presence of IL-1β have been shown to impair matrix production through
downregulating TGF-β receptor II expression, whilst upregulating the NF-κB pathway [101–103]. This
hypothesis was supported by a recent investigation, whereby there was an upregulation in TGF-β
receptor I and II expression in physioxia MSC chondrogenesis in the presence of IL-1β compared to a
downregulation in these receptors in the corresponding hyperoxic condition [99].
As well as the documented increase in inflammatory cytokines, the process of OA has also been
found to increase in oxygen tension within the joint [22]. Reoxygenation of physioxia MSCs mimics
the changes in oxygen tension during OA. In vitro experiments demonstrated that reoxygenating
MSC chondrogenic pellets in the presence of TNF-α showed an increase in aggrecanolysis with
subsequent upregulation in ADAMTS4/5 and MMP expression [85]. Thus, physioxia helps to suppress
inflammatory cytokine-inhibited MSC chondrogenesis via suppression of matrix degradative enzymes
and restoration of TGF-β receptors [99].
5. Physioxia Mechanisms in MSC Chondrogenesis
5.1. Hypoxia Inducible Factors (HIF): HIF-1α
Investigations of the mechanism controlling the chondrogenic response under physioxia have
noted the importance of the hypoxia-inducible factor (HIF) genes. The HIF genes belong to the basic
helix-loop-helix (bHLH)-Per-Ant-Sim (PAS) family of transcription factors [104–106]. There are three
HIF genes, HIF-1, HIF-2 and HIF-3, which consist of two sub-units, an unstable oxygen-sensitive alpha
sub-unit and a stable oxygen-insensitive beta sub-unit. The most studied is HIF-1α, which has been
described to be essential in cartilage development [34,35]. Under hyperoxic conditions, HIF-1α is
hydroxylated by PHDs and this exposes 4-hydroxyproline residues on the molecules. These exposed
residues are recognised by the von-Hippel-Lindau (VHL) E3 ubiquitin ligase complex, resulting in
its proteasomal degradation. Alongside this process, FIH hydroxylates the asparagine residue on
HIF-1α, thereby preventing its binding to the co-factor p300 (Figure 2a). In contrast, physioxia inhibits
PHD and FIH hydroxylation, enabling HIF-1α to translocate the nucleus and dimerize with HIF-1β
(Figure 2b).
HIF-1α activation upregulates the expression of physioxia-sensitive genes that include the cartilage
transcription factors, SOX5, SOX6 and SOX9, plus matrix genes, COL2A1 and ACAN [72,73,77,92].
It has been shown that HIF-1α interacts with SOX9 to upregulate COL2A1 and ACAN, whilst
downregulating COL10A1 expression under physioxia [92]. However, using either cadmium
chloride (chemical physioxia inhibitor) or HIF-1α dominant negative plasmid on physioxia-cultured
chondrogenic MSCs reduced SOX9, COL2A1 and ACAN expression, whilst COL10A1 expression
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was increased. The importance of HIF-1α was further supported in a recent study, whereby
chondrogenically differentiating HIF-1α deleted murine adipose MSCs under physioxia and developed
micromasses with reduced GAG and collagen II content compared to controls [73]. Furthermore,
an analysis of different HIF-1α hydroxylase inhibitors that chemically-induced physioxia effects
under hyperoxia via HIF-1α stabilisation was also performed [36]. Dimethyloxalylglycine (DMOG),
a competitive inhibitor of PHD and FIH, was found to induce the most stable articular chondrocyte
phenotype in MSC chondrogenesis compared with other forms of chemically-induced physioxia.
Application of the HIF-1α/-β complex inhibitor, acriflavine, on DMOG induced MSC chondrogenesis
and downregulated SOX9 and COL2A1 gene expression, whilst upregulating COL10A1 and increasing
hypertrophic chondrogenesis. This indicates that stable HIF-1α is an important component involved in
the physioxic chondrogenic response (Figure 3a).
Figure 3. The pathways controlling the response of physioxia MSC chondrogenesis. (a) HIF-1α upon
translocation into the nucleus and dimerization with HIF-1β leads to upregulation of chondrogenic
matrix gene expression, whereas (b) HIF-2α nuclear translocation and dimerization results in an
upregulation in cartilage hypertrophic and matrix degradation enzyme gene expression. The effect
of HIF-2α can be countered by the upregulation of (c) HIF-3α, which upon activation, counters the
upregulation in hypertrophic and matrix degradation gene expression. (d) The PI3K/Akt/FOXO
pathway is activated under physioxia in response to HIF-1α translocation and helps to maintain
chondrocyte phenotype via reduction in chondrocyte hypertrophy markers (green arrow direction
symbolizes positive upregulation or downregulation in chondrogenic or hypertrophic genes; red arrow
direction symbolizes negative upregulation in hypertrophic and matrix degradative enzyme gene
expression; dotted arrow depicts HIF-1α, HIF-2α or HIF-3α nuclear translocation).
Additionally, stable HIF-1α expression has been demonstrated to induce genes associated with
the glycolysis pathway both in articular chondrocytes and chondrogenic MSCs [57,71,82]. Articular
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chondrocytes have highly glycolytic metabolism due to their in vivo environment and they undergo
cellular senescence upon hyperoxic culture due to the production of reactive oxygen species [54,55,58].
Chondrogenic MSCs have also shown the same cellular metabolism during differentiation, and
physioxia helps sustain this glycolytic metabolism. Thus, activation and stabilisation of the
HIF-1α/HIF-1β complex could be a factor in achieving a stable articular chondrocyte phenotype.
5.2. HIF-2α
HIF-2α or EPAS-1 has been investigated in chondrocytes and MSCs with regards to its expression
both in physioxia and OA cartilage [107–110]. Coimbra et al. [109] demonstrated that HIF-2α was
expressed on an mRNA level in both normal and osteoarthritic chondrocytes under hyperoxic
conditions. This result has been replicated in a recent investigation, whereby HIF-1α and HIF-2α
were expressed under hyperoxic and physioxic conditions in both healthy and OA chondrocytes [31].
HIF-2α expression in hypertrophic and osteoarthritic chondrocytes has been a major focus area
with contrary results regarding its function in these particular processes. In embryonic mouse tibial
cartilage, HIF-2α expression was located in the hypertrophic zone alongside chondrocytes expressing
hypertrophic markers, COL10A1 and MMP13 [110]. HIF-2α overexpression in a mouse chondrocyte cell
line (ATDC5) resulted in an upregulation of hypertrophic, OA-associated (e.g., COL10A1, MMP13 and
vascular endothelial growth factor (VEGF)) and osteogenic (e.g., RUNX2, osteopontin) genes. Furthermore,
an analysis of healthy and OA cartilage from human donors indicated greater HIF-2α expression with
increasing OA grade. The results were also supported by an independent study (Figure 3b) [107].
These studies also included mouse models to understand whether these in vitro effects
were observed in vivo [107,110]. In one study, transgenic HIF-2α overexpressing mice using
promoter and enhancer regions of mouse COL2A1 gene were developed to understand the in vivo
response [107]. With age, there was increased cartilage degradation with the concomitant expression
of MMPs, aggrecanses and downstream catabolic targets, nitric oxide synthase (NOS2) and
prosteoglandin-endoperoxide synthase-2 (PTGS2). Saito et al. (2010) [110] generated heterozygous
HIF-2α knockout (HIF-2α+/−) mice that had a larger hypertrophic zone with a reduced bone area
compared to wild type mice, indicating that HIF-2α insufficiency prevents chondrocyte hypertrophy
and subsequent matrix degradation and vascularization. Furthermore, use of either collagenase
injection or a displaced medial meniscus (DMM) model to induce osteoarthritis in these heterozygous
mice demonstrated no cartilage degeneration and a suppression of MMP and aggrecanase expression
and downstream catabolic targets, NOS2 and PTGS2 [107]. Thus, these models indicate that HIF-2α
expression results in cartilage destruction, whilst its inhibition prevents OA and endochondral bone
development. Studies investigating the effects of inflammatory cytokines (IL-1β and IL-6) on mouse
articular chondrocytes showed that an increase in HIF-2α expression induced cartilage destruction via
the downstream activation of the NF-κB pathway, a well-described OA mechanism [107,111].
However, these early publications have been questioned by recent investigations that replicated
the conditional HIF-2α knockout mouse model and demonstrated that it only induced a delay in
endochondral ossification with no change in COL10A1 expression and no correlation in human subjects
between HIF-2α expression and idiopathic OA [112–114]. Furthermore, in-vitro physioxic culture
of human articular chondrocytes or chondrogenic MSCs has been shown to upregulate HIF-2α and
subsequently promotes cartilage matrix gene expression and formation [26,42,72]. A commentary
suggested that differences in mouse and human cartilage, particularly with respect to cartilage loading
and thickness, mean that HIF-2α in humans and larger animals has evolved into an anabolic gene
rather than a catabolic gene described in mouse studies [114]. Additionally, the in vitro experiments
examining HIF-2α overexpression were conducted under hyperoxia; thus, it is not known how this
would be influenced under physioxia. Therefore, the function of HIF-2α remains elusive and further
studies are required in both chondrocytes and chondrogenic MSCs under physioxia to understand its
contribution to chondrogenesis and cartilage homeostasis.
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5.3. HIF-3α
The third isoform, HIF-3α, has only recently been investigated in chondrogenesis [115–117].
Articular chondrocytes upon redifferentiation expressed HIF-3α micromass pellet cultures with greater
expression under physioxia, although it had a lower gene expression level compared to HIF-1α and
HIF-2α under the same conditions [115]. A reason for the differences in transcript levels may be related
to only a small number of chondrocytes expressing the gene. However, the fact that it was highly
expressed in physioxic cultures and corresponded to the upregulation in cartilage matrix genes during
redifferentiation suggested that it was contributory to the chondrocyte phenotype. Furthermore,
there is evidence that upregulated HIF-3α expression under physioxia inhibits COL10A1 and MMP13
expression, whilst knockdown of this gene upregulates these OA markers under the same conditions
in a Ewing sarcoma cell line [116].
A recent study investigated HIF-3α expression in articular chondrocytes and chondrogenic
MSCs under physioxia and hyperoxia to understand whether its expression was associated with
preventing hypertrophy [117]. Chondrogenic MSCs under physioxia and hyperoxia showed a low
HIF-3α expression, whilst there was higher expression for COL10A1 and MMP13. In contrast,
redifferentiated articular chondrocytes had a higher HIF-3α expression and downregulation in
COL10A1 and MMP13, independent of the oxygen condition. Furthermore, OA chondrocytes were
found to have a downregulation in HIF-3α expression compared with healthy articular chondrocytes.
Analysis of human embryonic growth plate cartilage demonstrated that HIF-3α expression was greatest
in the precursor chondrocyte region, whilst hypertrophic chondrocytes exhibited minimal HIF-3α
expression but had maximal expression for COL10A1 and MMP13 compared with other regions within
the growth plate [117]. These findings indicate that HIF-3α is a regulator of chondrocyte hypertrophy,
whereby its expression prevents hypertrophic gene expression and is diminished in cells with an
upregulation in hypertrophic genes such as OA chondrocytes and chondrogenically differentiated
MSCs (Figure 3c).
Investigations into HIF-3α expression, specifically in the previously described high and low
GAG MSC donors could lead to an understanding of how HIF-3α can control MSC chondrogenic
hypertrophy especially under physioxia. Furthermore, there is evidence that HIF-3α expression inhibits
downstream targets of HIF-1α and HIF-2α. Based on investigations on articular chondrocytes and
the described literature, it has been postulated that HIF-3α stabilisation inhibits the catabolic effects
exerted by HIF-2α under physioxia [117]. The inter-relationship between these HIF genes in physioxia
MSC chondrogenesis requires further investigation.
5.4. PI3K/Akt/FOXO Pathway
A process that has been gradually investigated in OA research is the process of apoptosis, as
this contributes to the initiation of the disease via chondrocyte cell death. Furthermore, the classical
process of endochondral ossification has been thought to involve the apoptosis of hypertrophic
chondrocytes that initially express COL10A1 and RUNX2, although there is now an evolving
paradigm that is contrary to this process and involves the transdifferentation of chondrocytes into
osteoblasts [118–120]. Thus, anti-apoptotic pathways are a potential mechanism for preventing
chondrogenic MSC hypertrophy.
One relevant mechanistic pathway that has been investigated in MSC chondrogenesis is the
PI3K/Akt pathway [93,121–124]. Transgenic mice containing an Akt fusion protein that enables
constitutive Akt activation in articular cartilage resulted in highest Akt phosphorylation in resting and
proliferative chondrocytes but reduced expression in hypertrophic chondrocytes [121]. An embryonic
limb explant model using limbs from wild type and transgenic Akt mice was used to understand
the significance of the PI3K/Akt pathway with respect to cartilage development. Following 5 days
of culture, Akt activation increased the proliferative and reduced the hypertrophic zone within the
limb. Use of a PI3K inhibitor (LY294002) on wild-type limbs only, reversed this effect and increased
the hypertrophic zone within cartilage. These explant results were replicated in vitro, using human
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synovial stromal cells (hSSCs) in a pellet culture model. Lentivirally transduced hSSCs that expressed
Akt gene via application of 4-hydroxytamoxifen, had increased pellet size and GAG deposition that
corresponded with elevated SOX9, COL2A1 and ACAN expression. Gene expression of COL10A1 and
RUNX2 was downregulated under these conditions. However, inhibition of PI3K using LY294002 in
hSSCs undergoing chondrogenesis demonstrated an inverse effect, whereby there was decreased pellet
size and GAG deposition, whilst there was an upregulation in hypertrophy genes. Thus, this pathway
contributes to the control of hypertrophy during chondrogenesis and has been studied further [122].
The PI3K/Akt pathway was specifically investigated in MSC chondrogeneis to understand
whether it is involved in the suppression of hypertrophy under physioxia [93]. A downregulation in
COL10A1 and RUNX2 gene expression and reduced collagen X staining was observed for physioxia
MSC chondrogenic pellets. They also describe an increase in the percentage of apoptotic cells (active
caspase-3 and -8) within chondrogenic pellets under hyperoxia compared with physioxia. Western
blot analysis confirmed that Akt was phosphorylated in chondrogenic pellets under physioxia. Use of
the PI3K inhibitor (wortmannin) in physioxia chondrogenic pellets showed that blocking downstream
Akt phosphorylation resulted in a downregulation in chondrogenic gene expression (SOX9, COL2A1,
ACAN) and an upregulation in RUNX2 and COL10A1 gene expression. These data were supported
by immunohistochemical staining whereby there was increased collagen X and reduced GAG and
collagen II staining in wortmannin treated pellets. Furthermore, there was a greater percentage of
apoptotic cells (active caspase-3 and caspase-8) within physioxia chondrogenic pellets in the presence
of the inhibitor.
One of the downstream targets of the PI3K/Akt pathway is the Forkhead-box class O (FOXO)
transcription factors that consist of four members, FOXO1, FOXO3, FOXO4 and FOXO6 [125,126].
FOXO1 and FOXO3 were expressed within normal articular cartilage, localised within the superficial
zone and middle zone of the tissue. However, phosphorylation of FOXO1 and FOXO3 provokes
nuclear export into the cytoplasm and subsequent degradation [123]. Previous studies have shown
that FOXO1 and FOXO3 phosphorylation within cartilage leads to cell death and osteoarthritis due
to the loss of autophagy genes that are known to protect chondrocytes from stress and are under
the control of FOXO3 [127,128]. This was demonstrated in human cartilage, as OA cartilage had
reduced expression for both FOXO1 and FOXO3 in the superficial zone compared to healthy cartilage,
but had greater expression within the middle zone due chondrocyte clustering and phosphorylation
which changed from the nucleus to the cytoplasm [123]. The importance of FOXO genes in articular
cartilage homeostasis was further demonstrated, as FOXO1 and FOXO3 knockout mice developed
more severe age-related OA compared with control mice, whilst the expression of autophagy genes was
downregulated in triple knockout (FOXO1, -3 and -4) mice [124]. Furthermore, adenoviral expression
of FOXO1 in human OA chondrocytes upregulated autophagy genes and countered the detrimental
effects of IL-1β. Thus, the FOXO genes are important contributors to cartilage homeostasis.
In physioxic MSC chondrogenesis, FOXO transcription factors with respect to cartilage
hypertrophy have also been investigated [93]. FOXO1/FOXO3 was found to be expressed in physioxic
chondrogenesis. However, inhibition of these transcription factors either via leptomycin B or
4-Hydroxynoneal replicated the response for physioxia chondrogenesis in the presence of wortmannin,
whereby there was downregulation in chondrogenic gene expression, an upregulation in RUNX2 and
COL10A1 gene expression with an increase in collagen X staining within these pellets. Furthermore,
markers of apoptosis, active caspase-3 and caspase-8, were found to increase in physioxia chondrogenic
pellets in the presence of FOXO inhibitors.
Thus, the PI3K/Akt/FOXO pathway (Figure 3d) may be a critical pathway in chondrogenesis with
respect to controlling the suppression of hypertrophy and cartilage homeostasis. This pathway also
involves HIF-1α and therefore the interactions between these transcription factors would require further
investigation. Furthermore, how FOXO expression upregulates autophagy genes that help to protect
against cartilage damage has not been determined, particularly with respect to MSC chondrogenesis
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in the presence of inflammatory cytokines (e.g., IL-1β) and the mechanism countering its inhibition
under physioxia.
6. Summary
In general, physioxia has an anabolic effect on MSC chondrogenesis whereby there is an
upregulation in chondrogenesis genes (SOX9, COL2A1, ACAN) and a concomitant increased
matrix deposition both within pellets and scaffolds when compared with hyperoxic conditions.
In contrast to hyperoxic culture, physioxic chondrogenesis significantly downregulates the expression
of hypertrophic genes, COL10A1 and MMP13, although subsequent staining suggests that physioxia
does not completely suppress collagen X production, particularly for donors whose cells produce a
high amount of GAG (Tables 1 and 2). Implantation of physioxia preconditioned chondrogenic MSCs
in nude mice and rabbit models replicated in vitro results in stable cartilage formation with reduced
bone formation compared with hyperoxic MSC chondrogenic implants [81,82,92]. However, a similar
study using a sheep model resulted in no differences in cartilaginous repair between physioxic and
hyperoxic preconditioned chondrogenic implants [51]. More careful selection of MSC preparations
may be required, as in spite of the downregulation of COL10A1 and MMP13 in high and low GAG
donors, collagen X staining was present in both donor types under physioxia, indicating only the
suppression of hypertrophy [33]. To completely inhibit the hypertrophy in MSC chondrogenesis,
additional environmental stimuli are required to stabilise the chondrogenic phenotype. Mechanical
stimuli has been known to enhance cartilage matrix production in MSC chondrogenesis [129–131].
One form of stimulation is hydrostatic pressure that involves fluid pressurisation without cellular
deformation [132,133]. Theoretical models have described that this form of loading can help maintain
the chondrocyte phenotype and prevent hypertrophy [134,135]. However, there are contrary results in
the literature; in some studies, hydrostatic pressure prevented MSC hypertrophy, but there are also
publications indicating an upregulation in hypertrophic genes [136–142]. It would be of interest to
investigate the combination of physioxia and hydrostatic pressure during MSC chondrogenesis.
MSCs and chondrocyte co-culture models have been tested to examine the effects on the two
cell types [67,143–145]. It was hypothesized that the cross-talk between cell types could help to
improve the cartilage tissues for in vivo implantation. It has been shown that direct MSC-chondrocyte
co-cultures prevent cartilage hypertrophy [143]. It has been demonstrated that co-culturing MSCs and
chondrocytes under physioxia helped to increase both cartilage formation and reduce hypertrophy
compared to MSC monocultures under the same conditions [67]. Further investigations into
MSC-chondrocyte co-culture systems under physioxia, possibly with loading, are warranted.
Physioxia helps counter the detrimental effects of inflammatory cytokines during in-vitro
chondrogenesis [74]. However, the underlying mechanisms controlling the response have not been
established. The HIFs have been the primary focus of the majority of studies on this phenomenon.
It appears that HIF-1α promotes the upregulation of chondrogenic matrix gene expression and HIF-3α
may help to stabilise the chondrogenic phenotype [34,35,105,117]. In contrast, some studies indicate
that HIF-2α upregulates both hypertrophic genes and matrix degradative enzymes [107,108,110,111].
However, there is also evidence that HIF-2α is also involved in the chondrogenic anabolic response
in both MSCs and chondrocytes under physioxia [26,42,72]. Further investigations are required to
understand the function of HIF-2α in the MSC chondrogenic response in physioxia, particularly in the
regulation of inflammatory cytokines, as a means to using the HIF-related pathways to modulate the
chondrocyte phenotype.
The PI3K/Akt/FOXO pathway (Figure 3d) is involved in preventing age-related OA; ectopic
FOXO expression in OA chondrocytes in the presence of IL-1β upregulated genes associated with
autophagy, thus countering the inhibitory effects of IL-1β [124]. This pathway has also been shown to
be involved in reducing apoptosis and MSC chondrogenic hypertrophy in physioxia [93]. The reduction
in apoptosis within chondrogenic pellets of MSCs may be related to the upregulation of autophagy
genes that could also be a potential reason for the countering effect of physioxia on cytokine-inhibited
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chondrogenesis. Thus, further investigations are required into how the PI3K/Akt/FOXO pathway
can contribute to alleviating cytokine-inhibited MSC chondrogenesis under physioxia, particularly
with respect to autophagy genes and whether it can be manipulated to provide a fully protective effect.
Another forkhead box transcription factor, FOXA, has also been implicated in the control of cartilage
hypertrophy and subsequent endochondral ossification; therefore, further investigation into MSC
chondrogenesis in physioxia could also consider its influence on the process [146].
7. Future Directions and Outlook
A STRING analysis was performed to investigate the possible interactions between the physioxia
responsive pathway genes and chondrogenic genes (Figures 4 and 5) [147]. The plots describe the
relationships between proteins based on experimental and theoretical results compiled and evaluated
from various databases and predicts the probability of interactions between them (Figures 4 and 5). The
analysis indicates a strong interaction or discrete clouds between the PI3K/AKT1/FOXO genes and
the chondrogenic genes. In the first instance, PI3KCA is the central player with strong relationships
between AKT and the different FOXO and FOXA genes evaluated. In terms of chondrogenic genes,
COL2A1 and ACAN are the central players. These discrete clouds have no direct interactions with a
common gene between them (Figures 4 and 5). Potentially, one common link between the two clouds
is TGF-β receptor I, as the analysis shows a probable connection with PI3KCA. Therefore, one pathway
for future investigation is the canonical and non-canonical TGF-β pathways and observing whether
the PI3K/Akt pathway is stimulated by this process [148]. Interestingly, the HIF genes are separated
from the chondrogenic genes, with the only connection between HIF-1α and SOX9, as described in
this review [34]. The analysis also supports the experimental findings for the interaction between the
PI3K/Akt/FOXO pathway and HIF-1α (Figure 5) [121]. However, it is noteworthy that the analysis
does not show a direct interaction between the HIFs and PI3K/Akt genes with respect to chondrogenic
gene expression, whilst the probability that there is a relationship between these distinct clouds is low.
Thus, the STRING evaluations demonstrate that further investigations are required in understanding
the underlying mechanisms controlling physioxia MSC chondrogenesis.
Since the phenotype of MSC-derived chondrocytes is not optimal, alternative cell types are
being considered for use in the treatment of early OA focal defects. Recent investigations in cartilage
tissue engineering have begun to evaluate a cell population within the superficial layer of articular
cartilage, termed articular cartilage progenitor cells (ACPs) [33,149–152]. ACPs are isolated via
fibronectin adherence and can be clonally expanded to high population doublings without a loss
in chondrogenic potential, unlike MSC populations that progressively lose their chondrogenicity
at similar doublings [149,151]. Furthermore, clonal ACPs have reduced collagen X staining and
markers for osteogenesis compared to bone marrow-derived MSCs [33,150]. Under physioxia, ACP
clonal populations demonstrated a significant downregulation in COL10A1 and MMP13 relative
to hyperoxia and also exhibited no collagen X staining and protein expression in all ACP clones.
In contrast, hyperoxic ACPs showed a clonal variability in collagen X staining, whereby there was
either no or abundant collagen X staining, depending upon the clone [33]. Thus, ACPs are an
alternative and potentially optimal cell source for the treatment of early OA focal defects, and physioxic
preconditioning helps stabilise the chondrocyte phenotype.
In summary, culturing MSCs at physioxia increases proliferation and induces a greater anabolic
response during chondrogenesis. Furthermore, physioxia supresses hypertrophy as judged by the
downregulation in COL10A1 and MMP13 expression, although it does not completely inhibit the
process. Whether physioxic preconditioning provides beneficial effects upon implantation in vivo
is not yet established. The underlying mechanisms controlling the physioxic response remain to be
elucidated and may offer new targets for therapies if novel pathways are identified.
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Figure 4. STRING database analysis based upon genes and proteins under the influence of physioxia
and chondrogenesis, which describes the interactions based on the database analysis between proteins.
Figure 5. STRING database analysis based upon genes and proteins under the influence of physioxia
and chondrogenesis, which describes the probability of interactions between proteins.
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